TG Therapeutics (NASDAQ:TGTX – Get Free Report) and Fractyl Health (NASDAQ:GUTS – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares TG Therapeutics and Fractyl Health”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TG Therapeutics | $616.29 million | 14.29 | $447.18 million | $2.74 | 21.00 |
| Fractyl Health | $90,000.00 | 870.18 | -$140.95 million | ($0.88) | -0.56 |
Profitability
This table compares TG Therapeutics and Fractyl Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TG Therapeutics | 55.22% | 73.49% | 34.14% |
| Fractyl Health | N/A | -1,362.10% | -84.89% |
Insider and Institutional Ownership
58.6% of TG Therapeutics shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Fractyl Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
TG Therapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Fractyl Health has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for TG Therapeutics and Fractyl Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TG Therapeutics | 2 | 1 | 6 | 0 | 2.44 |
| Fractyl Health | 1 | 1 | 3 | 0 | 2.40 |
TG Therapeutics currently has a consensus target price of $63.00, suggesting a potential upside of 9.47%. Fractyl Health has a consensus target price of $5.50, suggesting a potential upside of 1,017.89%. Given Fractyl Health’s higher possible upside, analysts clearly believe Fractyl Health is more favorable than TG Therapeutics.
Summary
TG Therapeutics beats Fractyl Health on 11 of the 14 factors compared between the two stocks.
About TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
About Fractyl Health
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
